Dostarlimab is a monoclonal antibody medication used to treat advanced or metastatic endometrial cancer. It works by blocking a protein called PD-1, which is found on certain types of cancer cells and helps them to evade the body’s natural immune system. By blocking this protein, dostarlimab helps the immune system to recognize and attack the cancer cells. Dostarlimab is only available as an intravenous infusion and is usually administered once every 3 weeks. Common side effects include fatigue, nausea, skin rash, and diarrhea.
Dostarlimab, sold under the brand name Jemperli, is a medication used as an immunotherapy for the treatment of certain types of endometrial cancer and other solid tumors. It is a programmed death receptor-1 (PD-1) inhibitor, which is a type of immunotherapy that works by helping the body's immune system recognize and attack cancer cells.
Dostarlimab is given as an intravenous infusion every three to six weeks. The most common side effects of dostarlimab include fatigue, nausea, diarrhea, constipation, and rash. More serious side effects can occur, including immune-mediated problems in any part of the body, such as the lungs, bowels, or endocrine glands. Dostarlimab is not recommended for use during pregnancy or breastfeeding.
Dostarlimab is a relatively new medication, and it is still being studied to determine its long-term effects. However, it has shown promise as a treatment for certain types of cancer.